Pattern recognition receptors (PRR, [13]) participate in the innate immune response to microbial agents, the stimulation of which leads to activation of intracellular enzymes and regulation of gene transcription. PRR include both cell-surface and intracellular proteins, including toll-like receptors (TLR), nucleotide-binding oligomerization domain-like receptors (NLR, also known as NOD-like receptors) and the mannose receptor family (ENSFM00250000004089). PRR may be divided into signalling-associated members, identified here, and endocytic members (such as the mannose receptor family), the function of which appears to be to recognise particular microbial motifs for subsequent cell attachment, internalisation and destruction.
PRRs express multiple leucine-rich regions to bind a range of microbially-derived ligands, termed PAMPs or pathogen-associated molecular patterns, which includes peptides, carbohydrates, peptidoglycans, lipoproteins, lipopolysaccharides, and nucleic acids.
Toll-like receptor family
Members of this family share significant homology with the interleukin-1 receptor family and appear to require dimerization either as homo- or heterodimers for functional activity. Heterodimerization appears to influence the potency of ligand binding substantially (e.g. TLR1/2 and TLR2/6, [14-15]). TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are cell-surface proteins, while other members are associated with intracellular organelles, signalling through the MyD88-dependent pathways (with the exception of TLR3). As well as responding to exogenous infectious agents, it has been suggested that selected members of the family may be activated by endogenous ligands, such as hsp60 [9].
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
NOD-like receptor family
Structural analysis has identified a common motif of a mid-peptide located nucleotide-binding and oligomerization (NACHT) domain, which allows division of NOD-like receptors into three subfamilies, NLRC (or NODs), NLRP (or NALP) and IPAF [11]. NLRC members are named on the basis of a sequence motif expressed at their N-termini, the caspase recruitment domain (CARD), while NLRP members have a pyrin domain. NLRs express C-terminal leucine-rich regions which have regulatory function and appear to recognize the microbial products to which the NLRs respond. NLRC family members recruit a serine/threonine kinase RIPK2 (receptor-interacting serine/threonine kinase 2, also known as CARD3, CARDIAK, RICK, RIP2, ENSG00000104312) leading to signalling through NFκB and MAP kinase. NLRP family members, upon activation, recruit adaptor proteins (e.g. Asc also known as PYCARD, CARD5, TMS-1, ENSG00000103490). Activated NLRs associate in multiprotein complexes, known as inflammasomes [11], allowing the recruitment of caspases.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
NLRP3 has also been reported to respond to host-derived products, known as danger-associated molecular patterns, or DAMPs, including uric acid [8], ATP, L-glucose, hyaluronan and amyloid β [11].
Loss-of-function mutations of NLRP3 are associated with cold autoinflammatory and Muckle-Wells syndromes.
Barton, GM; Kagan, JC. (2009) A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol., 9 (8): 535-42. [PMID:19556980]
Buchanan, MM; Hutchinson, M; Watkins, LR; Yin, H. (2010) Toll-like receptor 4 in CNS pathologies. J. Neurochem., 114 (1): 13-27. [PMID:20402965]
Celis, E. (2007) Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res., 67 (17): 7945-7. [PMID:17804699]
Chao, W. (2009) Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am. J. Physiol. Heart Circ. Physiol., 296 (1): H1-12. [PMID:19011041]
Chiron, D; Jego, G; Pellat-Deuceunynck, C. (2010) Toll-like receptors: expression and involvement in multiple myeloma. Leuk. Res., 34 (12): 1545-50. [PMID:20594595]
Downes, CE; Crack, PJ. (2010) Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?. Br. J. Pharmacol., 160 (8): 1872-88. [PMID:20649586]
Ehlers, M; Ravetch, JV. (2007) Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol., 28 (2): 74-9. [PMID:17197239]
Garantziotis, S; Hollingsworth, JW; Zaas, AK; Schwartz, DA. (2008) The effect of toll-like receptors and toll-like receptor genetics in human disease. Annu. Rev. Med., 59: 343-59. [PMID:17845139]
Hennessy, EJ; Parker, AE; O'Neill, LA. (2010) Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov, 9 (4): 293-307. [PMID:20380038]
Hirsch, I; Caux, C; Hasan, U; Bendriss-Vermare, N; Olive, D. (2010) Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol., 31 (10): 391-7. [PMID:20832362]
Hori, M; Nishida, K. (2008) Toll-like receptor signaling: defensive or offensive for the heart?. Circ. Res., 102 (2): 137-9. [PMID:18239139]
Kanzler, H; Barrat, FJ; Hessel, EM; Coffman, RL. (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med., 13 (5): 552-9. [PMID:17479101]
Könner, AC; Brüning, JC. (2011) Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol. Metab., 22 (1): 16-23. [PMID:20888253]
Lecat, A; Piette, J; Legrand-Poels, S. (2010) The protein Nod2: an innate receptor more complex than previously assumed. Biochem. Pharmacol., 80 (12): 2021-31. [PMID:20643110]
Li, H; Sun, B. (2007) Toll-like receptor 4 in atherosclerosis. J. Cell. Mol. Med., 11 (1): 88-95. [PMID:17367503]
Marsh, BJ; Williams-Karnesky, RL; Stenzel-Poore, MP. (2009) Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience, 158 (3): 1007-20. [PMID:18809468]
Marshak-Rothstein, A; Rifkin, IR. (2007) Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol., 25: 419-41. [PMID:17378763]
Monie, TP; Bryant, CE; Gay, NJ. (2009) Activating immunity: lessons from the TLRs and NLRs. Trends Biochem. Sci., 34 (11): 553-61. [PMID:19818630]
O'Neill, LA; Bowie, AG. (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol., 7 (5): 353-64. [PMID:17457343]
O'Neill, LA; Sheedy, FJ; McCoy, CE. (2011) MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol., 11 (3): 163-75. [PMID:21331081]
Sabroe, I; Parker, LC; Dower, SK; Whyte, MK. (2008) The role of TLR activation in inflammation. J. Pathol., 214 (2): 126-35. [PMID:18161748]
Saitoh, S; Miyake, K. (2009) Regulatory molecules required for nucleotide-sensing Toll-like receptors. Immunol. Rev., 227 (1): 32-43. [PMID:19120473]
Sanjuan, MA; Milasta, S; Green, DR. (2009) Toll-like receptor signaling in the lysosomal pathways. Immunol. Rev., 227 (1): 203-20. [PMID:19120486]
Schroder, K; Tschopp, J. (2010) The inflammasomes. Cell, 140 (6): 821-32. [PMID:20303873]
Shaw, PJ; Lamkanfi, M; Kanneganti, TD. (2010) NOD-like receptor (NLR) signaling beyond the inflammasome. Eur. J. Immunol., 40 (3): 624-7. [PMID:20201016]
Takeuchi, O; Akira, S. (2010) Pattern recognition receptors and inflammation. Cell, 140 (6): 805-20. [PMID:20303872]
Trinchieri, G; Sher, A. (2007) Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol., 7 (3): 179-90. [PMID:17318230]
Wenzel, J; Tormo, D; Tüting, T. (2008) Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects. Handb Exp Pharmacol, (183): 201-20. [PMID:18071661]
Werling, D; Jann, OC; Offord, V; Glass, EJ; Coffey, TJ. (2009) Variation matters: TLR structure and species-specific pathogen recognition. Trends Immunol., 30 (3): 124-30. [PMID:19211304]
1. Alexopoulou, L; Holt, AC; Medzhitov, R; Flavell, RA. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413 (6857): 732-8. [PMID:11607032]
2. Hayashi, F; Smith, KD; Ozinsky, A; Hawn, TR; Yi, EC; Goodlett, DR; Eng, JK; Akira, S; Underhill, DM; Aderem, A. (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature, 410 (6832): 1099-103. [PMID:11323673]
3. Heil, F; Ahmad-Nejad, P; Hemmi, H; Hochrein, H; Ampenberger, F; Gellert, T; Dietrich, H; Lipford, G; Takeda, K; Akira, S; et al.. (2003) The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol., 33 (11): 2987-97. [PMID:14579267]
4. Hemmi, H; Kaisho, T; Takeuchi, O; Sato, S; Sanjo, H; Hoshino, K; Horiuchi, T; Tomizawa, H; Takeda, K; Akira, S. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol., 3 (2): 196-200. [PMID:11812998]
5. Hemmi, H; Takeuchi, O; Kawai, T; Kaisho, T; Sato, S; Sanjo, H; Matsumoto, M; Hoshino, K; Wagner, H; Takeda, K; et al.. (2000) A Toll-like receptor recognizes bacterial DNA. Nature, 408 (6813): 740-5. [PMID:11130078]
6. Ingalls, RR; Monks, BG; Savedra, R; Christ, WJ; Delude, RL; Medvedev, AE; Espevik, T; Golenbock, DT. (1998) CD11/CD18 and CD14 share a common lipid A signaling pathway. J. Immunol., 161 (10): 5413-20. [PMID:9820516]
7. Kawasaki, K; Akashi, S; Shimazu, R; Yoshida, T; Miyake, K; Nishijima, M. (2000) Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J. Biol. Chem., 275 (4): 2251-4. [PMID:10644670]
8. Martinon, F; Pétrilli, V; Mayor, A; Tardivel, A; Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440 (7081): 237-41. [PMID:16407889]
9. Ohashi, K; Burkart, V; Flohé, S; Kolb, H. (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol., 164 (2): 558-61. [PMID:10623794]
10. Poltorak, A; He, X; Smirnova, I; Liu, MY; Van Huffel, C; Du, X; Birdwell, D; Alejos, E; Silva, M; Galanos, C; et al.. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 282 (5396): 2085-8. [PMID:9851930]
11. Schroder, K; Tschopp, J. (2010) The inflammasomes. Cell, 140 (6): 821-32. [PMID:20303873]
12. Schwandner, R; Dziarski, R; Wesche, H; Rothe, M; Kirschning, CJ. (1999) Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem., 274 (25): 17406-9. [PMID:10364168]
13. Takeuchi, O; Akira, S. (2010) Pattern recognition receptors and inflammation. Cell, 140 (6): 805-20. [PMID:20303872]
14. Takeuchi, O; Kawai, T; Mühlradt, PF; Morr, M; Radolf, JD; Zychlinsky, A; Takeda, K; Akira, S. (2001) Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol., 13 (7): 933-40. [PMID:11431423]
15. Takeuchi, O; Sato, S; Horiuchi, T; Hoshino, K; Takeda, K; Dong, Z; Modlin, RL; Akira, S. (2002) Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol., 169 (1): 10-4. [PMID:12077222]
16. Yoshimura, A; Lien, E; Ingalls, RR; Tuomanen, E; Dziarski, R; Golenbock, D. (1999) Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol., 163 (1): 1-5. [PMID:10384090]
|
@GuidetoPHARM Like us on Facebook Privacy and Cookie Policy |

